Instanyl is a medicine used to treat breakthrough pain in adults with cancer. Breakthrough pain is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers. Instanyl is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain. Instanyl contains the active substance fentanyl.
Therapeutic Indication
### Therapeutic indication Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
Therapeutic Area (MeSH)
ATC Code
N02AB03
ATC Item
fentanyl
Pharmacotherapeutic Group
Analgesics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Fentanyl citrate | N/A | 芬太尼 |
EMA Name
Instanyl
Medicine Name
Instanyl
Aliases
N/ANo risk management plan link.
